196 related articles for article (PubMed ID: 25029971)
21. Clinical research for rare disease: opportunities, challenges, and solutions.
Griggs RC; Batshaw M; Dunkle M; Gopal-Srivastava R; Kaye E; Krischer J; Nguyen T; Paulus K; Merkel PA;
Mol Genet Metab; 2009 Jan; 96(1):20-6. PubMed ID: 19013090
[TBL] [Abstract][Full Text] [Related]
22. Their lives in their hands.
Branca MA
Nat Biotechnol; 2019 Nov; 37(11):1255-1260. PubMed ID: 31690883
[No Abstract] [Full Text] [Related]
23. Putting translational science on to a global stage.
Gilliland CT; Zuk D; Kocis P; Johnson M; Hay S; Hajduch M; Bietrix F; Aversa G; Austin CP; Ussi AE
Nat Rev Drug Discov; 2016 Apr; 15(4):217-8. PubMed ID: 27032820
[TBL] [Abstract][Full Text] [Related]
24. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
25. Solving for x: accelerators could speed search for rare disease therapies.
Wolfson W
Chem Biol; 2013 Dec; 20(12):1435-7. PubMed ID: 24359846
[No Abstract] [Full Text] [Related]
26. Rare disease registries: a call to action.
Lacaze P; Millis N; Fookes M; Zurynski Y; Jaffe A; Bellgard M; Winship I; McNeil J; Bittles AH
Intern Med J; 2017 Sep; 47(9):1075-1079. PubMed ID: 28891182
[TBL] [Abstract][Full Text] [Related]
27. Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective.
Wong EH; Yocca F; Smith MA; Lee CM
Int J Neuropsychopharmacol; 2010 Oct; 13(9):1269-84. PubMed ID: 20716397
[TBL] [Abstract][Full Text] [Related]
28. Scaling genetic resources: New paradigms for diagnosis and treatment of rare genetic disease.
Vockley J; Defay T; Goldenberg AJ; Gaviglio AM
Am J Med Genet C Semin Med Genet; 2023 Mar; 193(1):77-86. PubMed ID: 36448938
[TBL] [Abstract][Full Text] [Related]
29. Personalized medicine for rare neurogenetic disorders: can we make it happen?
van Eeghen AM; Bruining H; Wolf NI; Bergen AA; Houtkooper RH; van Haelst MM; van Karnebeek CD
Cold Spring Harb Mol Case Stud; 2022 Feb; 8(2):. PubMed ID: 35332073
[TBL] [Abstract][Full Text] [Related]
30. Personalized Medicine: What's in it for Rare Diseases?
Schee Genannt Halfmann S; Mählmann L; Leyens L; Reumann M; Brand A
Adv Exp Med Biol; 2017; 1031():387-404. PubMed ID: 29214584
[TBL] [Abstract][Full Text] [Related]
31. Establishing Patient Registries for Rare Diseases: Rationale and Challenges.
Boulanger V; Schlemmer M; Rossov S; Seebald A; Gavin P
Pharmaceut Med; 2020 Jun; 34(3):185-190. PubMed ID: 32215853
[TBL] [Abstract][Full Text] [Related]
32. Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge.
McCarthy C; Lara Gallego B; Trapnell BC; McCormack FX
Adv Exp Med Biol; 2017; 1031():419-442. PubMed ID: 29214586
[TBL] [Abstract][Full Text] [Related]
33. 'IRDiRC Recognized Resources': a new mechanism to support scientists to conduct efficient, high-quality research for rare diseases.
Lochmüller H; Le Cam Y; Jonker AH; Lau LP; Baynam G; Kaufmann P; Lasko P; Dawkins HJ; Austin CP; Boycott KM
Eur J Hum Genet; 2017 Feb; 25(2):162-165. PubMed ID: 27782107
[TBL] [Abstract][Full Text] [Related]
34. Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies.
Lekstrom-Himes J; Brooks PJ; Koeberl DD; Brower A; Goldenberg A; Green RC; Morris JA; Orsini JJ; Yu TW; Augustine EF
Am J Med Genet C Semin Med Genet; 2023 Mar; 193(1):30-43. PubMed ID: 36738469
[TBL] [Abstract][Full Text] [Related]
35. [Rare diseases: Innovation laboratories for human health].
Braun S
Presse Med; 2012 May; 41 Suppl 1():S48-50. PubMed ID: 22464890
[No Abstract] [Full Text] [Related]
36. Clinical, Pathological, and Ethical Considerations for the Conduct of Clinical Trials in Dogs with Naturally Occurring Cancer: A Comparative Approach to Accelerate Translational Drug Development.
Regan D; Garcia K; Thamm D
ILAR J; 2018 Dec; 59(1):99-110. PubMed ID: 30668709
[TBL] [Abstract][Full Text] [Related]
37. [The stakes of pre- and post-market authorization development and clinical assessment].
Schwebig A
Presse Med; 2012 May; 41 Suppl 1():S6-8. PubMed ID: 22483770
[No Abstract] [Full Text] [Related]
38. Current Advances in Clinical Trials for Rare Disease Populations: Spotlight on the Patient.
Winter E; Schliebner S
Curr Rev Clin Exp Pharmacol; 2022; 17(1):39-45. PubMed ID: 33726656
[TBL] [Abstract][Full Text] [Related]
39. From scientific discovery to treatments for rare diseases - the view from the National Center for Advancing Translational Sciences - Office of Rare Diseases Research.
Kaufmann P; Pariser AR; Austin C
Orphanet J Rare Dis; 2018 Nov; 13(1):196. PubMed ID: 30400963
[TBL] [Abstract][Full Text] [Related]
40. [The time has come of a therapeutic (re)positioning of the ultra-rare diseases].
Martinat C; Peschanski M
Med Sci (Paris); 2018 Dec; 34(12):1019-1021. PubMed ID: 30623755
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
